181 related articles for article (PubMed ID: 38443119)
1. Novel Clinical Applications of Topical Ruxolitinib: A Case Series.
Zundell MP; Al-Dehneem R; Song T; Yousif J; Gottlieb AB
J Drugs Dermatol; 2024 Mar; 23(3):188-190. PubMed ID: 38443119
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
3. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
Grossmann MC; Haidari W; Feldman SR
J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
Kang C
Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
Gong X; Chen X; Kuligowski ME; Liu X; Liu X; Cimino E; McGee R; Yeleswaram S
Am J Clin Dermatol; 2021 Jul; 22(4):555-566. PubMed ID: 33982267
[TBL] [Abstract][Full Text] [Related]
7. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year.
Hu W; Thornton M; Livingston RA
Am J Clin Dermatol; 2024 Mar; 25(2):327-332. PubMed ID: 38243107
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata.
Tembunde Y; Kindred C
J Drugs Dermatol; 2024 May; 23(5):378-379. PubMed ID: 38709705
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
[TBL] [Abstract][Full Text] [Related]
10. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
Dogra S; Sharma A; Mehta H; Sarkar R
Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
[TBL] [Abstract][Full Text] [Related]
13. Off-label Studies on the Use of Ruxolitinib in Dermatology.
Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
[TBL] [Abstract][Full Text] [Related]
14. Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report.
Powers CM; Verma H; Orloff J; Piontkowski AJ; Tiersten A; Lamb A; Gulati N
J Dermatolog Treat; 2024 Dec; 35(1):2336118. PubMed ID: 38565207
[TBL] [Abstract][Full Text] [Related]
15. Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N; Turchin I
Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
[TBL] [Abstract][Full Text] [Related]
16. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
Mancuso-Stewart E; Rodger J; Zirwas M
Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
[TBL] [Abstract][Full Text] [Related]
17. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
18. Impact of JAK/STAT inhibitors on human monocyte-derived-macrophages stimulated by cigarette smoke extract and lipopolysaccharide.
Verres Y; da Silva CO; Aljebawi B; Bodin A; Barreto E; Lagente V; Victoni T
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1187-1196. PubMed ID: 35876719
[TBL] [Abstract][Full Text] [Related]
19. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
20. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
